GHK-Cu vs Glutathione

The distinction that mattersBoth marketed for skin, both frequently offered by IV infusion clinics. Neither has evidence supporting intravenous cosmetic use, and IV glutathione has specific regulator warnings against it.

	GHK-Cu Cosmetic Ingredient	Glutathione Limited Approval
Evidence rating	3/5 Moderate Evidence rating 3 out of 5: Moderate	3/5 Moderate Evidence rating 3 out of 5: Moderate
Regulatory status	Established cosmetic ingredient with human topical data. Injectable use is unapproved and unstudied.	Lawful as an oral supplement. Injectable glutathione is approved in the Philippines only as an adjunct to cisplatin chemotherapy; no injectable is FDA-approved for any systemic use, and US compounding of it rests on interim enforcement discretion while the substance is under evaluation. Injectable use for skin lightening or wellness is unapproved everywhere.
Category	Skin & Cosmetic	Bone, Muscle & Other
Drug class	Naturally occurring copper-binding tripeptide	Endogenous tripeptide antioxidant (glutamate-cysteine-glycine)
Route	Topical (well studied); injectable (not studied)	Oral, intravenous, liposomal, inhaled
Half-life	Commonly quoted as 30–60 minutes — that figure is an estimate repeated by suppliers and search summaries, not a measurement, and the same sources elsewhere give 1–2 hours or 4. No human pharmacokinetic study of GHK-Cu has been published for any route, so there is no measured half-life to report. What is established: rat work shows the tripeptide is cleared from plasma and broken to the dipeptide His-Lys, and once the peptide bonds are cut the copper does not leave with it but transfers to albumin, so the copper outlasts the peptide by far. Endogenous plasma GHK falls with age, but that is a concentration, not a half-life.	~14 minutes (14.1 +/- 9.2) after intravenous dosing in healthy adults.
Sequence length	3 residues	3 residues
Molecular weight	401.9 Da	307.3 Da
Studied in	A handful of small controlled human studies: a randomised, evaluator-blinded, vehicle-controlled trial of a copper tripeptide gel in diabetic foot ulcers (whose larger 511-patient successor failed), a maker-funded 8-week split-face wrinkle trial in 40 women, a small trial after laser resurfacing that was negative on blinded measures, and an 18-person eyebrow study. The cosmetic facial and eye-cream results were reported as 2002 conference abstracts rather than papers, and no controlled trial supports GHK-Cu alone for scalp hair. The bulk of the literature is fibroblast and keratinocyte culture plus rodent wound, lung and liver models. No controlled human study of any injected route.	Randomised double-blind trials of pharmaceutical-grade IV glutathione given alongside cisplatin or oxaliplatin to blunt neuropathy (about 50 to 150 patients each, 1990s to 2002; a 2014 Cochrane review pooled seven such trials); a negative 21-patient randomised pilot in Parkinson disease; five small oral trials for skin tone; one non-randomised, unblinded IV skin-lightening study of 32 women with a non-significant result and frequent liver-enzyme derangement. No controlled trial of IV glutathione for fatigue, immunity or wellness in healthy adults.
Who should avoid it	Wilson disease or copper metabolism disorders (systemic use) Known copper allergy Broken or actively infected skin without medical advice	IV glutathione for cosmetic purposes Asthma (inhaled forms have triggered bronchospasm) Pregnancy for injectable use
Legal status	Lawful as a cosmetic ingredient. Injectable preparations are unapproved.	Lawful as an oral supplement. Injectable cosmetic use is unapproved and subject to import alerts.

Benefits — GHK-Cu

Improved skin firmness and wrinkle depth
Small facial studies reported modest improvements in wrinkle depth, skin density and elasticity against comparison creams. The best, a randomised 8-week split-face trial, was maker-funded and could not separate GHK-Cu from its carrier; the older cream studies exist only as conference abstracts.
Wound healing acceleration
A randomised, blinded trial found faster closure of diabetic foot ulcers, but the maker's larger 511-patient trial failed. Animal wound studies consistently show faster closure and better-organised collagen.
Collagen and elastin stimulation
Robust fibroblast data showing upregulation of matrix synthesis.
Hair follicle effects
Cell and animal work shows effects on hair-follicle cells. No controlled trial of GHK-Cu alone has tested scalp hair loss; the human trial usually cited used a copper-free GHK compound.
Antioxidant and anti-inflammatory activity
Reduces oxidative damage markers in laboratory models.

Benefits — Glutathione

Essential endogenous antioxidant
Its physiological importance is not in question — depletion is associated with oxidative stress in many disease states.
Supports hepatic detoxification
Central to phase II conjugation; the basis of N-acetylcysteine's use as the antidote in acetaminophen overdose.
Modest skin-lightening signal orally
Small randomized trials of oral glutathione showed measurable reductions in melanin index over several weeks.
Reduces platinum chemotherapy neuropathy in small trials
Randomised double-blind trials in gastric, colorectal and ovarian cancer found fewer patients developing clinically significant neuropathy when pharmaceutical-grade glutathione was infused around cisplatin or oxaliplatin, without blunting tumour response; a Cochrane review pooled seven such trials. Subjective toxicity scales, small numbers, and a supervised oncology setting: this is the legitimate injectable use, and it is nothing like a wellness drip.
Better raised via precursors
N-acetylcysteine and whey protein reliably raise intracellular glutathione and have far better evidence than direct supplementation.

Risks & cons — GHK-Cu

Injectable use has no evidence base
The credible data is topical. Injecting copper peptides for systemic anti-aging has not been studied and introduces copper-load questions.
Copper accumulation concern
Chronic high-dose systemic copper exposure carries hepatic and neurologic risk; contraindicated in Wilson disease.
Skin irritation and contact dermatitis
Occurs in a minority of topical users, more often at higher concentrations.
Incompatibility with vitamin C and some acids
Direct co-application can destabilise the complex; separate application times are advised.
Wide variation in product concentration
Cosmetic products differ enormously in actual GHK-Cu content and formulation quality.

Risks & cons — Glutathione

Endotoxin in dietary-supplement-grade powder
The injectable glutathione market runs on bulk powder, and twice, in 2019 and 2026, compounders used powder labelled for dietary supplements rather than for injection. Both times patients developed fever, chills, hypotension and shock-like reactions within minutes to hours, traced to bacterial endotoxin, which survives sterilisation and is not caught by a sterility test. In 2026 at least 30 patients were affected across several states and three pharmacies recalled product. A vial can be sterile and still pyrogenic; only a bacterial endotoxin test on the batch would show it, and a 503A pharmacy is not required to run one on every lot.
IV skin-lightening infusions are unapproved and unsafe
FDA and several national regulators have warned against them following reports of severe adverse events including Stevens-Johnson syndrome, renal dysfunction and thyroid effects.
Poor oral bioavailability
Standard oral glutathione is largely degraded in the gut; much of the supplement market ignores this.
Infection risk from unregulated infusion clinics
Non-sterile compounding and IV administration in non-medical settings has caused serious infections.
Antioxidant supplementation is not uniformly beneficial
High-dose antioxidants can blunt exercise adaptation and, in some trial contexts, have shown harm.

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.